NicOx

Last updated
Nicox S.A.
Company type Société Anonyme
Euronext:  COX
Industryresearch and development in biotechnology  OOjs UI icon edit-ltr-progressive.svg
Founded1996 (1996)
Headquarters,
Website www.nicox.com

Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health. [1] Nicox is headquartered in Sophia Antipolis, France, and its Chairman and CEO is Michele Garufi. [2] [3]

Contents

Nicox is listed on Euronext Paris [4] (Compartment B: Mid-Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three programs in development, and it has two U.S. Food and Drug Administration (FDA) approved products. [5]

Pipeline

Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure (IOP) in patients with glaucoma. [6] NCX 470 is designed to release both bimatoprost, which is marketed under the brand name LUMIGAN, and nitric oxide following instillation into the eye. Bimatoprost is a prostaglandin analog, the most widely used class of drugs for IOP lowering in patients with open angle glaucoma and ocular hypertension. [7] [8]

The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. [9] Nicox generates revenue from VYZULTA(R) in glaucoma and ZERVIATE(TM), or cetirizine ophthalmic solution, in allergic conjunctivitis. It has ongoing partnerships with Bausch & Lomb, Eyevance Pharmaceuticals and Ocumension Therapeutics. [10] [11]

Agreement with Ocumension

In 2019, Nicox and Ocumension Therapeutics signed an agreement to allow Ocumension the rights to develop and commercialize Zerviate, a cetirizine ophthalmic solution, for the Chinese and South East Asian markets. The deal would see Nicox eligible for up to $17.2 million, along with tiered royalties of between 5 and 9% of the net sales. In July 2021 the deal was amended and Ocumension paid $2 million to Nicox as an advance payment of future development and regulatory milestones. [12]

Related Research Articles

<span class="mw-page-title-main">Glaucoma</span> Group of eye diseases

Glaucoma is a group of eye diseases that lead to damage of the optic nerve, which transmits visual information from the eye to the brain. Glaucoma may cause vision loss if left untreated. It has been called the "silent thief of sight" because the loss of vision usually occurs slowly over a long period of time. A major risk factor for glaucoma is increased pressure within the eye, known as intraocular pressure (IOP). It is associated with old age, a family history of glaucoma, and certain medical conditions or medications. The word glaucoma comes from the Ancient Greek word γλαυκός, meaning 'gleaming, blue-green, gray'.

<span class="mw-page-title-main">Prostaglandin</span> Group of physiologically active lipid compounds

Prostaglandins (PG) are a group of physiologically active lipid compounds called eicosanoids that have diverse hormone-like effects in animals. Prostaglandins have been found in almost every tissue in humans and other animals. They are derived enzymatically from the fatty acid arachidonic acid. Every prostaglandin contains 20 carbon atoms, including a 5-carbon ring. They are a subclass of eicosanoids and of the prostanoid class of fatty acid derivatives.

Prostaglandin analogues are a class of drugs that bind to a prostaglandin receptor.

<span class="mw-page-title-main">Betaxolol</span> Chemical compound

Betaxolol is a selective beta1 receptor blocker used in the treatment of hypertension and angina. It is also a adrenergic blocker with no partial agonist action and minimal membrane stabilizing activity. Being selective for beta1 receptors, it typically has fewer systemic side effects than non-selective beta-blockers, for example, not causing bronchospasm as timolol may. Betaxolol also shows greater affinity for beta1 receptors than metoprolol. In addition to its effect on the heart, betaxolol reduces the pressure within the eye. This effect is thought to be caused by reducing the production of the liquid within the eye. The precise mechanism of this effect is not known. The reduction in intraocular pressure reduces the risk of damage to the optic nerve and loss of vision in patients with elevated intraocular pressure due to glaucoma.

<span class="mw-page-title-main">Latanoprost</span> Chemical compound

Latanoprost, sold under the brand name Xalatan among others, is a medication used to treat increased pressure inside the eye. This includes ocular hypertension and open-angle glaucoma. Latanaprost is applied as eye drops to the eyes. Onset of effects is usually within four hours, and they last for up to a day.

<span class="mw-page-title-main">Timolol</span> Chemical compound

Timolol is a beta blocker medication used either by mouth or as eye drops. As eye drops it is used to treat increased pressure inside the eye such as in ocular hypertension and glaucoma. By mouth it is used for high blood pressure, chest pain due to insufficient blood flow to the heart, to prevent further complications after a heart attack, and to prevent migraines.

Ocular hypertension is the presence of elevated fluid pressure inside the eye, usually with no optic nerve damage or visual field loss.

<span class="mw-page-title-main">Carbonic anhydrase inhibitor</span> Class of pharmaceuticals

Carbonic anhydrase inhibitors are a class of pharmaceuticals that suppress the activity of carbonic anhydrase. Their clinical use has been established as anti-glaucoma agents, diuretics, antiepileptics, in the management of mountain sickness, gastric and duodenal ulcers, idiopathic intracranial hypertension, neurological disorders, or osteoporosis.

<span class="mw-page-title-main">Bimatoprost</span> Chemical compound

Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.

<span class="mw-page-title-main">Levobetaxolol</span> Chemical compound

Levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is marketed as a 0.25 or 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor.

<span class="mw-page-title-main">Unoprostone</span> Chemical compound

Unoprostone (INN) is a prostaglandin analogue. Its isopropyl ester, unoprostone isopropyl, was marketed under the trade name Rescula for the management of open-angle glaucoma and ocular hypertension.

COX-inhibiting nitric oxide donators (CINODs), also known as NO-NSAIDs, are a new class of nonsteroidal anti-inflammatory drug (NSAID) developed with the intention of providing greater safety than existing NSAIDs.

Naproxcinod (nitronaproxen) is a nonsteroidal anti-inflammatory drug (NSAID) developed by the French pharmaceutical company NicOx. It is a derivative of naproxen with a nitroxybutyl ester to allow it to also act as a nitric oxide (NO) donor. This second mechanism of action makes naproxcinod the first in a new class of drugs, the cyclooxygenase inhibiting nitric oxide donators (CINODs), that are hoped to produce similar analgesic efficacy to traditional NSAIDs, but with less gastrointestinal and cardiovascular side effects.

Brimonidine/timolol, sold under the brand name Combigan among others, is a fixed-dose combination medication eye drop used for the treatment of glaucoma. It is a combination of brimonidine and timolol.

<span class="mw-page-title-main">Tafluprost</span> Chemical compound

Tafluprost is a prostaglandin analogue. It is used topically to control the progression of open-angle glaucoma and in the management of ocular hypertension, alone or in combination with other medication. It reduces intraocular pressure by increasing the outflow of aqueous fluid from the eyes.

<span class="mw-page-title-main">Glaucoma medication</span> Eye condition medication

Glaucoma medication is divided into groups based on chemical structure and pharmacologic action. The goal of currently available glaucoma therapy is to preserve visual function by lowering intraocular pressure (IOP) in patients that have an increased intraocular pressure.

Ripasudil, a derivative of fasudil, is a rho kinase inhibitor drug used for the treatment of glaucoma and ocular hypertension.

<span class="mw-page-title-main">Latanoprostene bunod</span> Chemical compound

Latanoprostene bunod, sold under the brand name Vyzulta, is an ophthalmic medication used for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension. It targets the trabecular meshwork directly. It is a prostaglandin analog.

Bimatoprost/timolol, sold under the brand name Ganfort, is a medication for the treatment of certain conditions involving high pressure in the eyes, specifically open angle glaucoma and ocular hypertension. It is available as eye drops.

Posner–Schlossman syndrome (PSS) also known as glaucomatocyclitic crisis (GCC) is a rare acute ocular condition with unilateral attacks of mild granulomatous anterior uveitis and elevated intraocular pressure. It is sometimes considered as a secondary inflammatory glaucoma.

References

  1. "COX: Nicox Stock Price Quote - EN Paris - Bloomberg". Bloomberg News .
  2. "Here's a French Biotech Investors May Not Care About Enough". Bloomberg.com. Retrieved 2018-08-08.
  3. "Michele Garufi, PDG de NicOx".
  4. "| live".
  5. "Nicox S.A. (NICXF) Stock Price Today, Quote & News | Seeking Alpha".
  6. Clinical trial number NCT03657797 for "Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension" at ClinicalTrials.gov
  7. Sambhara, Deepak; Aref, Ahmad A. (2014). "Glaucoma management: relative value and place in therapy of available drug treatments". Therapeutic Advances in Chronic Disease. 5 (1): 30–43. doi:10.1177/2040622313511286. PMC   3871276 . PMID   24381726.
  8. "Prostaglandin analogs: The "gold standard" for glaucoma".
  9. Clinical trial number NCT03926026 for "Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis" at ClinicalTrials.gov
  10. "NICOX: Nicox Announces ZERVIATE Launch by Partner Eyevance Pharmaceuticals in the United States". Bloomberg.com. 31 March 2020.
  11. "BRIEF-Nicox Updates Agreement with Ocumension Therapeutics on ZERVIATE". Reuters. 11 March 2020. Archived from the original on June 11, 2020.
  12. NICOX (2021-07-05). "Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE® Agreement". GlobeNewswire News Room. Retrieved 2021-09-19.